Muscle-specific Pparg deletion causes insulin resistance

Nature Medicine

Volumn 9, Issue 12, 2003, Pages 1491-1497

  Hevener, Andrea L ^a   He, Weimin ^a   Barak, Yaacov ^c,d   Le, Jamie ^a   Bandyopadhyay, Gautam ^a   Olson, Peter ^b,d   Wilkes, Jason ^a   Evans, Ronald M ^d,e   Olefsky, Jerrold ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JACKSON LABORATORY   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE DISRUPTION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; INSULIN RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; GENE EXPRESSION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORTER TYPE 4; INSULIN; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 0346027235     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm956     Document Type: Article

References (49)

1. Harris, M.I. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey. 1988-1994 Diabetes Care 21, 518-524 (1998).
2. Meigs, J.B. Epidemiology of the metabolic syndrome. Am. J. Manag. Care 8, S283-S292 (2002).
3. Reaven, G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106, 286-288 (2002).
4. Suter, S.L., Nolan, J.L., Wallace, P., Gumbiner, B. & Olefsky, J. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15, 193-203 (1992).
5. Saitiel, A.R. & Olefsky, J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669 (1996).
6. Lehmann, J.M. et al. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J. Biol. Chem. 270, 12953-12956 (1995).
7. Ciaraldi, T.P., Gilmore, A. & Olefsky, J.M. In vitro studies on the action of CS-0455, a new anti-diabetic agent. Metabolism 39, 1056-1062 (1990).
8. El-Kebbi, I., Rosner, S. & Pollet, R.J. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43, 953-958 (1994).
9. Bowen, L., Steven, P.P., Stevenson, R. & Shulman, C.I. The effect of CP-68772, a thiazolidine derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40, 1025-1030 (1991).
10. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I. & Horikoshi, H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37, 1549-1558 (1998).
11. Kumar, S. et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39, 701-709 (1996).
12. Nolan, J.J., Ludvik, B., Beerdsen P., Joyce, M. & Olefsky, J. Improvements in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331. 1188-1193 (1994).
13. Braissant, O., Foufelle, F., Scott, C., Dauce, M. & Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β and γ in the adult rat. Endocrinology 137, 354-366 (1996).
14. Fajas, L. et al. Organization, promoter analysis and expression of the human PPARγ gene. J. Biol. Chem. 272, 18779-18789 (1997).
15. Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
16. Kliewer, S.A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA 91, 7355-7359 (1994).
17. Spiegelman, B.M. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514 (1998).
18. Mangelsdorf, D.J. & Evans, R.M. The RXR heterodimers and orphan receptors. Cell 83, 841-850 (1995).
19. Willson, T.M., Brown, P.J., Sternbach, D.D. & Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550 (2000).
20. Harris, P.K. & Kletzien, R.F. Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol. Pharamacol, 45, 439-445 (1994).
21. Auboeuf, D. et al. Tissue distribution and quantification of the expression of PPARs and LXRα in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 48, 1319-1327 (1997).
22. Rosen, E.D. et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4 621-627 (1999).
23. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.B. & Spiegelman, B.M. mPPAR-γ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224-1234 (1994).
24. Vidal-Puig, A.J. et al. Peroxisome-proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocoticoids. J. Clin. Invest. 99, 2416-2422 (1997).
25. Law, R.E. et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101, 1311-1318 (2000).
26. Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H. & Evans, R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ. Cell 93, 229-240 (1998).
27. Motojima, K., Passilly, P., Peters, J.M., Gonzalez, F.J. & Latruffe, N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273, 16710-16714 (1998).
28. Schoonjans, K., Staels, B. & Auwerx, J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302, 93-109 (1996).
29. Sears, I.B., MacGinnitie, M.A., Kovacs, L.G. & Graves, R.A. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator activated receptor γ. Mol. Cell Biol. 16, 3410-3418 (1996).
30. Tontonoz, P., Hu, E. & Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147-1156 (1994).
31. Young, P.W. et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 44, 1087-1092 (1995).
32. Wu, Z., Xie, Y., Bucher, N.L.R. & Farmer, S.R. PPARγ induces the insulin-dependent glucose transporter, GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101, 22-32 (1998).
33. Loviscach, M. et al. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43, 304-311 (2000).
34. Barak, Y. et al. PPARγ is required for placental, cardiac and adipose tissue development. Mol. Cell 4, 585-595 (1999).
35. Bruning, J.C. et al. A muscle-specific insulin receptor knockout exhibits features of metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2, 559-569 (1998).
36. Miles, P.D.G., Barak, Y., He, W., Evans, R.M. & Olefsky, J.M. Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105, 287-292 (2000).
37. Lee, Y.H., Giraud, J., Davis, R.J. & White, M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 278, 2896-2902 (2003).
38. Gavrilova, O. et al. Liver PPARγ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. (in the press).
39. Way, J.M. et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferators activated receptor γ activation has coordinate effects on gene expression in multiple insulin sensitive tissues. Endocrinology 142, 1269-1277 (2001).
40. Spiegelman, B.M. & Flier, J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87, 377-389 (1996).
41. Kahn, B.B. & Flier, J.S. Obesity and insulin resistance. J. Clin. Invest. 106, 473-481 (2000).
42. DeFronzo, R.A., Bonadonna, R.C. & Ferrannini, E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15, 318-368 (1992).
43. Kido, Y. et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2, J. Clin. Invest. 105, 199-205 (1999).
44. Smith, D. et al. In vivo glucose metabolism in the awake rat: tracer and insulin clamp studies. Metabolism 36, 1176-1186 (1987).
45. O'Goman, S., Dagenais, N.A., Qain, M. & Marchuk, Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. USA 94, 14602-14607 (1997).
46. Wilkes, J. & Bonen, A. Reduced insulin-stimulated glucose transport in denervated muscle is associated with impaired Akt-α activation. Am. J. Physiol. Endocrinol. Metab. 279, E912-E919 (2000).
47. Revers, R.R., Fink, R., Griffin, J., Olefsky, J.M. & Kolterman, O.G. Influence of hyperglycemia on effects in type II diabetes. J. Clin. Invest. 73, 664-672 (1984).
48. Frayn, K.N. & Maycock, P.F. Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. J. Lipid Res. 21, 139-144 (1980).
49. Steele, R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann. NY Acad. Sci. 82, 420-430 (1959).